Ian Cooper’s Stock Pick of the Week

Crispr  (CRSP)  UPDATE Keep an eye on CRISPR Therapeutics (CRSP), we said on November 1. “The gene editing stock is starting to take off after a favorable US FDA panel review of the drug exa-cel for sickle-cell disease. Now, should the US FDA approve it on the panel’s vote, we could be looking at the […]

Ian Cooper’s Stock Pick of the Week Read More »